Picture of Xvivo Perfusion AB logo

XVIVO — Xvivo Perfusion AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapFalling Star

Brief: Xvivo Perfusion Q4 EBITDA Loss Narrows To SEK 0.1 Mln

Jan 27 (Reuters) - Xvivo Perfusion AB  XVIVO.ST 

    * Q4 NET SALES AMOUNTED TO SEK 85.9 MILLION (60.3),
CORRESPONDING
TO AN INCREASE OF 42 PERCENT IN SEK AND 42 PERCENT ALSO IN LOCAL
CURRENCIES
    * Q4  NET SALES OF NON-DURABLE GOODS AMOUNTED TO SEK 74.0
MILLION
(54.9), CORRESPONDING TO AN INCREASE OF 35 PERCENT IN SEK AND 34
PERCENT IN LOCAL CURRENCIES
    * Q4 OPERATING PROFIT BEFORE DEPRECIATION AND AMORTIZATION
(EBITDA) AMOUNTED TO SEK- 0.1 MILLION (-6.5), CORRESPONDING TO
AN EBITDA MARGIN OF 0 PERCENT (-11)
    * Q4 ADJUSTED EBITDA AMOUNTED TO SEK 9.6 MILLION (6.8),
CORRESPONDING TO AN ADJUSTED EBITDA MARGIN OF 11 PERCENT (11)
    * Q4 NET PROFIT AMOUNTED TO SEK 12.2 MILLION (-19.6).
EARNINGS PER
SHARE AMOUNTED TO SEK 0.42 (-0.68)
    * Q4 EBIT SEK LOSS 8.3 MILLION VERSUS LOSS SEK 14.3 MILLION
YEAR
AGO

Source text for Eikon:  ID:nMFN1HQt5p 
Further company coverage:  XVIVO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))

Recent news on Xvivo Perfusion AB

See all news